"2009-01-01+01:00"^^ . "Testovan\u00FD model novorozeneck\u00E9ho screeningu cystick\u00E9 fibr\u00F3zy IRT/PAP nen\u00ED vhodn\u00FD pro vysokou fale\u0161nou negativitu a vysokou frekvenci potn\u00EDch test\u016F. Nejlep\u0161\u00ED parametry vykazuje model IRT/PAP/DNA se sn\u00ED\u017Een\u00FDmi cutoff hodnotami PAP."@cs . "0"^^ . . "Novorozeneck\u00FD screening (NS) cystick\u00E9 fibr\u00F3zy (CF) je zalo\u017Een na m\u011B\u0159en\u00ED koncetrace imunoreaktivn\u00EDho trypsinogenu (IRT) a DNA anal\u00FDze genu CFTR pro CF v such\u00FDch kapk\u00E1ch krve. DNA anal\u00FDzu lze nahradit stanoven\u00EDm proteinu spojen\u00E9ho s pankreatitidou (%22pancreatitis associated protein%22, PAP). Budou porovn\u00E1ny modely IRT/PAP a nov\u011B navrhovan\u00FD model IRT/PAP/DNA z hlediska \u00FA\u010Dinnosti, specifity, senzitivity a ekonomiky. V\u00FDstup projektu by se m\u011Bl st\u00E1t podkladem pro rozhodnut\u00ED o volb\u011B optim\u00E1ln\u00EDho modelu NS CF v \u010CR." . "2011-12-31+01:00"^^ . "The tested model of neonatal screening for cystic fibrosis IRT/PAP is not suitable for high false negativity and a high frequency of sweat tests. The IRT/PAP/DNA model with reduced cutoff values of PAP shows the best performance metrics."@en . " CFTR" . "1"^^ . . "2013-10-31+01:00"^^ . . . "0"^^ . . . . " fibrosis" . "Optimalizace novorozeneck\u00E9ho screeningu cystick\u00E9 fibr\u00F3zy." . . . . "http://www.isvav.cz/projectDetail.do?rowId=NS9986"^^ . . . "cystic; fibrosis; newborn; screening; genotyping; CFTR; IRT; PAP"@en . "Optimalization of newborn screening of cystic fibrosis"@en . " IRT" . . "NS9986" . . " newborn" . . "6"^^ . "6"^^ . " screening" . . " genotyping" . . . "cystic" . "Newborn screening for cystic fibrosis (NSCF) is based on examination of concentration of imunoreactive trypsinogen (IRT) and DNA analysis of CFTR gene in blood spots on screening cards. DNA analysis could be replaced with pancreatitis associated protein (PAP). The major aim of this study is to compare IRT/PAP scheme with new designed IRT/PAP/DNA scheme from the point of specifity, sensitivity and cost-benefit effectivity. The outcomes of this project will be decision about optimal routine NSCF scheme in the Czech Republic."@en . . .